期刊文献+

血栓性微血管病发病机制的研究进展 被引量:2

暂未订购
导出
摘要 血栓性微血管病(TMA)是一组临床病理综合征,病理表现主要为内皮细胞肿胀脱落、内皮下绒毛状物质沉积和血管腔内血小板聚集形成微血栓、血管腔内栓塞及红细胞碎裂等微血管系统异常。临床表现主要为微血管病性溶血乃至贫血、血小板减少及微循环中血栓造成的器官受累。经典的血栓性微血管病主要指溶血尿毒综合征(HUS)及血栓性血小板减少性紫癜(TTP),其它常见的血栓性微血管病病因还包括恶性高血压、硬皮病肾危象、妊娠相关的肾脏损害及抗磷脂综合征等。
作者 于峰 赵明辉
出处 《临床内科杂志》 CAS 2011年第11期731-733,共3页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献6

  • 1Ruggenenti P,Galli M,Remuzzi G.Hemolytic uremic syndrome,thrombotic thrombocytopenic purpura,and antiphospholipid antibody syndromes.In:Neilson EG and Couser WG eds.Immunologic renal diseases.2nd ed.Philadelphia:Lippincott-Raven Publishers,2001.1173-1202.
  • 2Pennington H.Escherichia coli O157.Lancet,2010,376:1428-1435.
  • 3Skerka C,Jozsi M,Zipfel PF,et al.Autoantibodies in haemolytic uraemic syndrome(HUS).Thromb Haemost,2009,101:227-232.
  • 4Delvaeye M,Noris M,De Vriese A,et al.Thrombomodulin mutations in atypical hemolytic-uremic syndrome.N Engl J Med,2009,361:345-357.
  • 5Skerka C,Zipfel PF,Muller D,et al.The autoimmune disease DEAPhemolytic uremic syndrome.Semin Thromb Hemost,2010,36:625-632.
  • 6Zhou Z,Jing H,Tao Z,et al.Effects of naturally occurring mutations in CUB-I domain on synthesis,stability,and activity of ADAMTS-13.Thromb Res,2009,124:323-327.

同被引文献18

  • 1Shi SF, Zhou FD, Zou WZ, et al. Acute kidney injury and bilateral symmetrical enlargement of the kidneys as first presentation of B-cell lymphoblastic lymphoma. Am J Kidney Dis, 2012, 60: 1044-1048.
  • 2George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood, 2010, 116: 4060-4069.
  • 3Wang FM, Yu F, Tan Y, et al. Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. Rheumatology (Oxford), 2012, 51: 2269-2277.
  • 4Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int, 2010, 77 : 820-S29.
  • 5Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome ( APS). J Thromb Haemost, 2006, 4 : 295-306.
  • 6Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol, 2012, 8 : 622-633.
  • 7Tsumagari T, Fukumoto S, Kinjo M, et al. Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol, 1985, 16:43-49.
  • 8yon Baeyer H. Plasmapheresis in thrombotic microangiopathy- associated syndromes : review of outcome data derived from clinical trials and open studies. Ther Apher, 2002, 6: 320-328.
  • 9Wyllie BF, Garg AX, Macnab J, et al. Members of the Canadian Apheresis Group. Thrombotic thrombocytopenic purpura/ haemolytic uraemic syndrome: a new index predicting response to plasma exchange. Br J Haematol, 2006, 132 : 204-209.
  • 10Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol, 2007, 136 : 146-149.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部